<DOC>
	<DOCNO>NCT00066586</DOCNO>
	<brief_summary>RATIONALE : High estrogen level may associate dense breast tissue increase risk develop breast cancer . Exemestane may effective preventing development breast cancer decrease estrogen level reduce breast density . PURPOSE : Randomized clinical trial study effectiveness exemestane prevent development breast cancer decrease estrogen level reduce breast density postmenopausal woman increase risk breast cancer .</brief_summary>
	<brief_title>Exemestane Reducing Breast Density Postmenopausal Women Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy exemestane decrease breast density least 1 grade postmenopausal woman increase radiological breast density increase risk breast cancer . - Determine whether decrease breast density sustain 1 year cessation drug participant . - Correlate grade breast density bone density baseline 1 year participant treat drug . - Determine overall safety drug , term bone lipid metabolism toxicity , participant . - Determine menopause-specific quality life participant treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Participants stratify accord baseline mammographic density grade ( 2 vs 3 v 4 v 5 v 6 ) . Participants randomize 1 2 treatment arm . - Arm I : Participants receive oral exemestane daily 1 year . - Arm II : Participants receive oral placebo daily 1 year . In arm , treatment continue absence disease unacceptable toxicity . Quality life assess baseline 3 , 6 , 9 , 12 , 18 , 24 month . Participants follow 18 24 month . PROJECTED ACCRUAL : A total 120 participant ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiologically confirm density occupy least 25 % breast tissue baseline mammogram* Grade 2 , 3 , 4 , 5 , 6 ( Boyd classification ) Participants different grade 2 breast classify accord high grade NOTE : *Performed within 6 month study entry Bone mineral density Tscore either posterioranterior spine hip ( femoral neck ) must great 2.0 standard deviation mean value peak bone mass young normal woman determine DEXA scan within past 6 month No concurrent breast cancer No prior invasive breast cancer ductal carcinoma situ No breast implant Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Postmenopausal Sex Female Menopausal status Postmenopausal , define 1 following : Over 50 year age spontaneous menses least 1 year 50 year age menses ( e.g. , spontaneous secondary hysterectomy ) within past year AND folliclestimulating hormone level within institution postmenopausal range Bilateral oophorectomy Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No cardiovascular disease No history myocardial infarction No history stroke No uncontrolled high blood pressure Other No uncontrolled metabolic endocrine disease No malabsorption syndrome No known hypersensitivity exemestane excipients No malignancy within past 5 year except curatively treat squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy More 3 month since prior exogenous estrogen and/or progesterone/progestin therapy More 6 month since prior selective estrogenreceptor modulators ( e.g. , tamoxifen , toremifene , raloxifene ) No concurrent selective estrogenreceptor modulators ( e.g. , tamoxifen , toremifene , raloxifene ) No concurrent steroid Vaginal estrogen allow ( e.g. , Estring® Vagifem® ) No concurrent compound cream Radiotherapy Not specify Surgery Not specify Other More 4 week since prior investigational agent No concurrent medication would preclude study endpoints No concurrent overthecounter product supplement consider estrogenic effect , include follow : Ginseng Ginkgo biloba Black cohosh Dong quai Fortified soy supplement ( e.g. , phytoestrogen preparation )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>breast cancer</keyword>
</DOC>